Quality First: Using Data to Inform Site Selection in CNS

March 28, 2019

Over 85% of new CNS drug trials fail to achieve the desired endpoints. Some fail because efficacy cannot be established. Others fail because of operational issues, including low enrollment and poor data management. Incorporating leading scientific concepts at the start of the trial can create a cascade of benefits throughout.

With proprietary technology, an unrivaled database, and a cadre of the world’s leading experts in the study of neuroscience and neurodegenerative disease, WCG MedAvante-ProPhase helps biopharma sponsors to mitigate the operational variability that interferes with good, clean science – a requisite to proper research.

Previous Flipbook
Optimizing SUSAR distribution in a connected– but unharmonized–world
Optimizing SUSAR distribution in a connected– but unharmonized–world

Steven Beales and Joe O’Rourke, vice president, business development talk through some of the difficulties ...

Next Flipbook
Don’t Do It Alone: To De-Risk Your Next Trial, Seek Outside Expertise
Don’t Do It Alone: To De-Risk Your Next Trial, Seek Outside Expertise

Due to evolving practices and increased regulatory attention on expert committee operations, sponsors are t...

Request a Genetics in Clinical Trials training session

What You'll Learn